BOSTON, MA, Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point-of-need, has raised $80 million in a Series B financing.

The round was led by Novalis LifeSciences and included new investors Illumina Ventures, Albany Capital and Catalio Capital Management, among others. They joined Northpond Ventures, Good Ventures, and other existing investors, bringing $111 million in total funding raised to date.